Remove category pharmaceuticals
article thumbnail

The Case for Procurement Transparency

Bill of Health

By Tara Davis and Nicola Soekoe In January 2021, the Director General of the World Health Organization (WHO) observed that the world was on the brink of a “catastrophic moral failure” if wealthier nations did not ensure the equitable distribution of COVID-19 vaccines.

article thumbnail

How Pharma Startups Can Remain Competitive in Today’s Market

HIT Consultant

In the Pharmaceutical industry, one of the major gaps is an effective, and personalized customer experience. . The COVID-19 pandemic drastically affected the way consumers prefer to receive medication and medical services. pharmaceutical industry will be worth $ 685.45 Adopting and Leveraging Technology.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Reasonable Pricing Clauses: A First Step Toward Ensuring Taxpayers a Fair Return on their Public R&D Investment

Bill of Health

By Nikhil Chaudhry and Reshma Ramachandran Earlier this month, the Department of Health and Human Services announced that it had successfully included a reasonable pricing provision in a $326M investment contract with Regeneron for development of a next generation monoclonal antibody therapy for COVID-19. pharmaceutical market.

COVID-19 205
article thumbnail

Why Companies Need Healthcare Commercial Intelligence

HIT Consultant

Healthcare commercial intelligence is a new category of software designed to help organizations address the complexity of product development and sales in the healthcare market. He has built several research-based businesses focused on providing the highest quality and most timely data in information-intensive industries.

article thumbnail

SQA Regulatory Surveillance Summary | Monthly Update 2024

SQA

The products had been improperly regularized in ANVISA as cosmetics since they are indicated for injectable use, a form that is not authorized for this category of product. The purpose of the note is to clarify that products for invasive aesthetic treatments cannot be regularized in the category of cosmetics.

FDA 52